Adaptimmune Therapeutics (NASDAQ:ADAP) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a report published on Friday morning. The firm issued a buy rating on the biotechnology company’s stock.

Separately, Mizuho decreased their price objective on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating on the stock in a research note on Wednesday, November 27th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Adaptimmune Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $2.18.

Adaptimmune Therapeutics Trading Up 3.9 %

NASDAQ:ADAP opened at $0.29 on Friday. Adaptimmune Therapeutics has a one year low of $0.26 and a one year high of $1.65. The business has a fifty day moving average price of $0.54 and a 200-day moving average price of $0.70. The firm has a market capitalization of $74.41 million, a price-to-earnings ratio of -1.32 and a beta of 2.52. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82.

Institutional Investors Weigh In On Adaptimmune Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. GSA Capital Partners LLP bought a new stake in Adaptimmune Therapeutics during the 3rd quarter valued at approximately $95,000. FMR LLC lifted its holdings in shares of Adaptimmune Therapeutics by 3.0% in the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after acquiring an additional 50,419 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Adaptimmune Therapeutics by 130.4% in the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 98,581 shares during the last quarter. Virtu Financial LLC lifted its position in Adaptimmune Therapeutics by 27.5% in the third quarter. Virtu Financial LLC now owns 101,008 shares of the biotechnology company’s stock worth $96,000 after buying an additional 21,769 shares during the last quarter. Finally, LPL Financial LLC boosted its stake in Adaptimmune Therapeutics by 106.5% during the fourth quarter. LPL Financial LLC now owns 183,479 shares of the biotechnology company’s stock worth $99,000 after buying an additional 94,623 shares during the period. 31.37% of the stock is owned by institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.